Further subgroup analysis revealed that, compared to diabetic populations, semaglutide had a more significant reduction in SBP ( 1.87, 95% CI 2.67 to 1.06, vs 5.02, 95% CI 6.10 to 3.94) and DBP ( 0.43, 95% CI 0.89 to 0.02, vs 1.96, 95% CI 3.12 to 0.80) in non-diabetic populations
A real-world analysis of approximately 8,000 patients from the Cleveland Clinic found considerably less weight regain than clinical trial data would predict largely because many real-world patients transition to another weight-loss agent, restart semaglutide, or maintain structured lifestyle interventions after stopping
Always read the label that comes with your specific vial
as a result, this treatment can be used to naturally boost your bodys own processes to lose excess weight